Rxivist logo

Author: Iksung Cho

  • Most recently observed institution: Novavax Inc., Gaithersburg, MD

Rankings

  • All-time downloads: 54,547 (rank: 4,673 )
  • Categories:
    • allergy and immunology: 7,939 (rank: 333 (tie) )
    • infectious diseases: 45,155 (rank: 1,638 )

Downloads per author, site-wide

Preprints

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

infectious diseases more details view paper
  • Downloaded 15,589 times
  • Download rankings, all-time:
    • Site-wide: 764
    • In infectious diseases: 268
  • Year to date:
    • Site-wide: 892
  • Since beginning of last month:
    • Site-wide: 7,826

First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine

infectious diseases more details view paper
  • Downloaded 10,175 times
  • Download rankings, all-time:
    • Site-wide: 1,323
    • In infectious diseases: 414
  • Year to date:
    • Site-wide: 17,255
  • Since beginning of last month:
    • Site-wide: 15,774

Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines

allergy and immunology more details view paper
  • Downloaded 8,042 times
  • Download rankings, all-time:
    • Site-wide: 1,792
    • In allergy and immunology: 15
  • Year to date:
    • Site-wide: 9,433
  • Since beginning of last month:
    • Site-wide: 27,345

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant

infectious diseases more details view paper
  • Downloaded 7,251 times
  • Download rankings, all-time:
    • Site-wide: 2,056
    • In infectious diseases: 579
  • Year to date:
    • Site-wide: 4,729
  • Since beginning of last month:
    • Site-wide: 21,002

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

infectious diseases more details view paper
  • Downloaded 5,076 times
  • Download rankings, all-time:
    • Site-wide: 3,336
    • In infectious diseases: 800
  • Year to date:
    • Site-wide: 10,533
  • Since beginning of last month:
    • Site-wide: 16,146

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

infectious diseases more details view paper
  • Downloaded 2,356 times
  • Download rankings, all-time:
    • Site-wide: 10,163
    • In infectious diseases: 1,581
  • Year to date:
    • Site-wide: 25,318
  • Since beginning of last month:
    • Site-wide: 41,483

Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults

infectious diseases more details view paper
  • Downloaded 1,930 times
  • Download rankings, all-time:
    • Site-wide: 13,755
    • In infectious diseases: 1,866
  • Year to date:
    • Site-wide: 12,105
  • Since beginning of last month:
    • Site-wide: 100,335

Comparison of the Safety and Immunogenicity of a Novel Matrix-M-adjuvanted Nanoparticle Influenza Vaccine with a Quadrivalent Seasonal Influenza Vaccine in Older Adults: A Randomized Controlled Trial

infectious diseases more details view paper
  • Downloaded 1,580 times
  • Download rankings, all-time:
    • Site-wide: 18,688
    • In infectious diseases: 2,228
  • Year to date:
    • Site-wide: 25,294
  • Since beginning of last month:
    • Site-wide: 51,955

Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine

infectious diseases more details view paper
  • Downloaded 1,246 times
  • Download rankings, all-time:
    • Site-wide: 27,307
    • In infectious diseases: 2,676
  • Year to date:
    • Site-wide: 76,498
  • Since beginning of last month:
    • Site-wide: 110,795

Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial

infectious diseases more details view paper
  • Downloaded 925 times
  • Download rankings, all-time:
    • Site-wide: 43,249
    • In infectious diseases: 4,293
  • Year to date:
    • Site-wide: 3,889
  • Since beginning of last month:
    • Site-wide: 4,288

Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial

infectious diseases more details view paper
  • Downloaded 377 times
  • Download rankings, all-time:
    • Site-wide: 131,778
    • In infectious diseases: None
  • Year to date:
    • Site-wide: 17,297
  • Since beginning of last month:
    • Site-wide: 2,747

PanLingua

News